KLIFS - the structural kinase database

Searching for structures with analogs of Tandutinib.

Search results (42 entries covering 23 PDB structures)

Kinase	Family	Group	PDB	Chain	(Alternate) Model	Orthosteric ligand	Organism	Details	Similarity (MFP)
EPHA2 (EphA2)	Eph	TK	5ia4	A	B	n-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Human	7168	0.42
AURKA (AurA)	Aur	Other	2c6e	A		n-{5-[(7-{[(2s)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}-6-methoxyquinazolin-4-yl)amino]pyrimidin-2-yl}benzamide	Human	1989	0.42
MET	Met	TK	6sdc	A	A	n-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Human	11532	0.42
EPHA2 (EphA2)	Eph	TK	5ia4	A	A	n-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Human	7189	0.42
EGFR	EGFR	TK	3ug2	A	A	gefitinib	Human	898	0.45
EGFR	EGFR	TK	2ity	A		gefitinib	Human	790	0.45
GAK	NAK	Other	5y80	A	A	gefitinib	Human	10329	0.45
GAK	NAK	Other	5y7z	A		gefitinib	Human	10332	0.45
STK10 (LOK)	STE20	STE	6i2y	B		n-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Human	10788	0.42
GAK	NAK	Other	5y80	A	B	gefitinib	Human	10330	0.45
EPHB4 (EphB4)	Eph	TK	2vwu	A		n-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine	Human	370	0.46
STK10 (LOK)	STE20	STE	6i2y	A		n-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Human	10787	0.42
GAK	NAK	Other	5y7z	B		gefitinib	Human	10331	0.45
KIT	PDGFR	TK	6gql	B		~{n}-[4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-2-(4-propan-2-yl-1,2,3-triazol-1-yl)ethanamide	Human	10357	0.41
KIT	PDGFR	TK	6gqj	B	B	2-[4-(6,7-dimethoxyquinazolin-4-yl)oxy-2-methoxy-phenyl]-~{n}-(1-propan-2-ylpyrazol-4-yl)ethanamide	Human	10356	0.41
KIT	PDGFR	TK	6gqk	A	A	~{n}-[4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-2-(1-ethylpyrazol-4-yl)ethanamide	Human	10355	0.42
KIT	PDGFR	TK	6gql	A		~{n}-[4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-2-(4-propan-2-yl-1,2,3-triazol-1-yl)ethanamide	Human	10362	0.41
KIT	PDGFR	TK	6gqj	B	A	2-[4-(6,7-dimethoxyquinazolin-4-yl)oxy-2-methoxy-phenyl]-~{n}-(1-propan-2-ylpyrazol-4-yl)ethanamide	Human	10358	0.41
EGFR	EGFR	TK	4i22	A		gefitinib	Human	823	0.45
EGFR	EGFR	TK	4wkq	A	A	gefitinib	Human	889	0.45
KDR	VEGFR	TK	6gqo	A	B	2-[4-(6,7-dimethoxyquinazolin-4-yl)oxy-2-methoxy-phenyl]-~{n}-(1-propan-2-ylpyrazol-4-yl)ethanamide	Human	10583	0.41
MAPK14 (p38a)	MAPK	CMGC	4a9y	A		n-(3-{[7-methoxy-6-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]amino}-4-methylphenyl)-2-morpholin-4-ylisonicotinamide	Human	5073	0.46
EGFR	EGFR	TK	3ug2	A	B	gefitinib	Human	819	0.45
MAPK14 (p38a)	MAPK	CMGC	2bak	A		n-(3-{[7-methoxy-6-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]amino}-4-methylphenyl)-2-morpholin-4-ylisonicotinamide	Human	5114	0.46
EGFR	EGFR	TK	2ito	A		gefitinib	Human	783	0.45
KIT	PDGFR	TK	6gqk	B	A	~{n}-[4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-2-(1-ethylpyrazol-4-yl)ethanamide	Human	10363	0.42
EGFR	EGFR	TK	2itz	A		gefitinib	Human	789	0.45
KDR	VEGFR	TK	6gqq	A	A	~{n}-[4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-2-(4-propan-2-yl-1,2,3-triazol-1-yl)ethanamide	Human	10581	0.41
KDR	VEGFR	TK	6gqp	A	A	~{n}-[4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-2-(1-ethylpyrazol-4-yl)ethanamide	Human	10582	0.42
KDR	VEGFR	TK	6gqp	A	B	~{n}-[4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-2-(1-ethylpyrazol-4-yl)ethanamide	Human	10584	0.42
KDR	VEGFR	TK	6gqo	A	A	2-[4-(6,7-dimethoxyquinazolin-4-yl)oxy-2-methoxy-phenyl]-~{n}-(1-propan-2-ylpyrazol-4-yl)ethanamide	Human	10580	0.41
AURKA (AurA)	Aur	Other	2c6e	B		n-{5-[(7-{[(2s)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}-6-methoxyquinazolin-4-yl)amino]pyrimidin-2-yl}benzamide	Human	2046	0.42
KIT	PDGFR	TK	6gqk	A	B	~{n}-[4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-2-(1-ethylpyrazol-4-yl)ethanamide	Human	10353	0.42
KDR	VEGFR	TK	6gqq	A	B	~{n}-[4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-2-(4-propan-2-yl-1,2,3-triazol-1-yl)ethanamide	Human	10585	0.41
KIT	PDGFR	TK	6gqj	A	B	2-[4-(6,7-dimethoxyquinazolin-4-yl)oxy-2-methoxy-phenyl]-~{n}-(1-propan-2-ylpyrazol-4-yl)ethanamide	Human	10354	0.41
KIT	PDGFR	TK	6gqj	A	A	2-[4-(6,7-dimethoxyquinazolin-4-yl)oxy-2-methoxy-phenyl]-~{n}-(1-propan-2-ylpyrazol-4-yl)ethanamide	Human	10364	0.41
KIT	PDGFR	TK	6gqk	B	B	~{n}-[4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-2-(1-ethylpyrazol-4-yl)ethanamide	Human	10360	0.42
EGFR	EGFR	TK	4wkq	A	B	gefitinib	Human	837	0.45
MET	Met	TK	3lq8	A	B	n-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Human	2964	0.42
MET	Met	TK	3lq8	A	A	n-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Human	2998	0.42
MET	Met	TK	6sd9	A		n-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Human	11531	0.42
MET	Met	TK	6sdc	A	B	n-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Human	11534	0.42